G01N33/56983

SEROLOGICAL ASSAY FOR ZIKA VIRUS INFECTION

The current invention provides compositions, methods, and kits for detecting the exposure to and infection by certain viruses. Specifically, the current invention allows for the rapid differential serological detection of exposure to, and infection by viruses. In particular, the current invention allows for the rapid serological detection of exposure to, and infection by Zika virus (ZIKV).

Electrically-Modulated Biosensors Using Electro-Active Waveguides

Immunosensors according to present embodiments combine a sandwich bioassay with an electro-active, integrated optical waveguide (EA-IOW) for the detection of infectious pathogens and other analytes from a sample, whereby the electro-active waveguide surface is functionalized with a capture antibody capable of specific binding with a particular antigen. This functionalized arrangement then promotes the binding of a secondary, labeled antibody serving as a redox probe, which produces an analytical signal having unique spectral and electrochemical properties for the detection of virus antigens, pathogens, and other analytes that bind to proteins.

PRE-ASSEMBLED, PROTECTED, CHEMICALLY STABLE, CHEMOSELECTIVE LINKERS
20190359566 · 2019-11-28 ·

Molecules compounds are provided having the structure in Formula I, or a salt thereof, wherein n1 is independently 0, 1, 2, or 3; n2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; n.sup.3 is from 0, 1, 2, or 3; n.sup.4 is 0 or 1; and n.sup.5 is 0, 1, 2, or 3; and wherein X is O, N, or S; Y, Z, XX, and YY are the same or different and are independently O or S; ZZ comprises nitrogen, oxygen, sulfur, or selenium; and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 are as described herein. Methods are also provided for the synthesis of and use of the provided molecules in applications for diagnostic testing.

Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
10487120 · 2019-11-26 · ·

Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

MONOCLONAL ANTIBODIES AGAINST HEMAGGLUTININ OF H5-SEROTYPE INFLUENZA VIRUSES AND THEIR USES, HYBRIDOMAS PRODUCING SAID ANTIBODIES, COMPOSITIONS AND DIAGNOSTIC KITS

The object of the invention are monoclonal antibodies against hemagglutinin of H5-serotype influenza viruses selected from the group comprising G-1-31-22, G-2-14-10, G-5-32-5, G-6-42-42, G-7-24-17 and G-7-27-18, having a broad application in immunoprophyiaxis and immunotherapy of infections evoked by H5-serotype influenza viruses in humans and animals. The invention also provides hybridomas producing said antibodies, as well as compositions and diagnostic kits containing said antibodies for the detection and typing of H5-serotype influenza viruses and antibodies against H5-serotype influenza viruses in biological samples.

HEMAGGLUTININ-SPECIFIC ANTIBODIES AND USES THEREOF

The present invention relates to hemagglutinin-specific antibodies, fragments thereof, and uses thereof. More specifically, these antibodies and fragments thereof are able to recognize antigen from multiple influenza strains.

METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION
20190353656 · 2019-11-21 · ·

The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

Devices and Methods for Detection of Viruses from Exhaled Breath
20240110914 · 2024-04-04 ·

Described herein is a sensor comprising a doped silicon layer, a graphene layer on the doped silicon layer, a molecularly imprinted polymer (MIP) layer on the graphene layer, and electrodes in operative arrangement with the MIP layer and configured to provide a signal indicative of resistance. The MIP layer is derived from a MIP monomer and functional monomer. Also described herein is a detector comprising a sensor described herein as well as methods of making and using the sensors and detectors, e.g., to detect an analyte, such as a virus.

RECOMBINANT CDHR3 PROTEIN FRAGMENTS INHIBIT RHINOVIRUS C BINDING AND REPLICATION
20240109948 · 2024-04-04 ·

The present invention provides soluble truncated peptides of CDHR3, recombinant variants thereof and methods of making these peptides. The present invention also provide methods of inhibiting rhinovirus C infection and an in vitro assay for screening for anti-viral agents against rhinovirus C.

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
20190346443 · 2019-11-14 ·

A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.